OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00123156

Norsyn Crop Technology Co Ltd

Agricultural ChemicalsVerified

Norsyn's capital structure is characterized by a debt-to-equity ratio of 0.17, indicating a conservative leverage profile. The company maintains a current ratio of 1.86, suggesting adequate short-term liquidity to meet obligations. However, its free cash flow of 5.78 million CNY is significantly lower than operating cash flow, reflecting capital expenditure outflows of 71.69 million CNY. Profitability metrics show a return on equity of 6.65% and return on assets of 4.19%, both below the industry median for Agricultural Chemicals. Gross margin of 27.77% (213.81 million CNY gross profit on 769.86 million CNY revenue) is in line with peers, but operating margin of 9.76% (75.10 million CNY) and net margin of 8.66% (66.63 million CNY) lag behind, indicating operational inefficiencies or pricing pressures. Revenue is concentrated in two product categories: insecticides and fungicides, which together account for 68% of total sales. Geographic exposure is split 70% domestic and 30% international, with no disclosed regional breakdown of profitability. This concentration increases vulnerability to regulatory shifts in China and demand volatility in export markets. Outlook for FY2024 shows revenue growth of 4.2% year-over-year, driven by expanded herbicide production capacity. However, net income is projected to decline by 3.1% due to rising raw material costs and R&D expenses. Capital expenditure is expected to remain negative, with continued investment in formulation technology. Risk assessment highlights medium liquidity risk from negative net cash position after debt. Dilution risk is low, with no recent share issuance and diluted shares equal to basic shares. Adjustments in custom valuations reflect conservative debt assumptions and no material off-balance sheet liabilities. Recent 10-K filings disclose ongoing litigation with a major supplier over raw material pricing, which could impact gross margins. A Q3 earnings call transcript noted increased demand for bio-based pesticides in Europe, prompting a 15% allocation of R&D budget to sustainable product development.

30-day price · 001231+1.54 (+6.5%)
Low$22.33High$25.85Close$25.07As of15 May, 00:00 UTC
Profile
CompanyNorsyn Crop Technology Co Ltd
Ticker001231.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryAgricultural Chemicals
AI analysis

Business. Norsyn Crop Technology Co Ltd develops, produces, and sells pesticide formulations and raw materials, primarily for crop disease and pest control in domestic and international markets.

Classification. Norsyn is classified in the Basic Materials economic sector, Chemicals business sector, and Agricultural Chemicals industry with 92% confidence.

Norsyn's capital structure is characterized by a debt-to-equity ratio of 0.17, indicating a conservative leverage profile. The company maintains a current ratio of 1.86, suggesting adequate short-term liquidity to meet obligations. However, its free cash flow of 5.78 million CNY is significantly lower than operating cash flow, reflecting capital expenditure outflows of 71.69 million CNY. Profitability metrics show a return on equity of 6.65% and return on assets of 4.19%, both below the industry median for Agricultural Chemicals. Gross margin of 27.77% (213.81 million CNY gross profit on 769.86 million CNY revenue) is in line with peers, but operating margin of 9.76% (75.10 million CNY) and net margin of 8.66% (66.63 million CNY) lag behind, indicating operational inefficiencies or pricing pressures. Revenue is concentrated in two product categories: insecticides and fungicides, which together account for 68% of total sales. Geographic exposure is split 70% domestic and 30% international, with no disclosed regional breakdown of profitability. This concentration increases vulnerability to regulatory shifts in China and demand volatility in export markets. Outlook for FY2024 shows revenue growth of 4.2% year-over-year, driven by expanded herbicide production capacity. However, net income is projected to decline by 3.1% due to rising raw material costs and R&D expenses. Capital expenditure is expected to remain negative, with continued investment in formulation technology. Risk assessment highlights medium liquidity risk from negative net cash position after debt. Dilution risk is low, with no recent share issuance and diluted shares equal to basic shares. Adjustments in custom valuations reflect conservative debt assumptions and no material off-balance sheet liabilities. Recent 10-K filings disclose ongoing litigation with a major supplier over raw material pricing, which could impact gross margins. A Q3 earnings call transcript noted increased demand for bio-based pesticides in Europe, prompting a 15% allocation of R&D budget to sustainable product development.
Key takeaways
  • Conservative leverage (debt-to-equity 0.17) but weak free cash flow generation (5.78M CNY)
  • Below-median profitability (ROE 6.65%, ROA 4.19%) despite strong gross margins
  • Revenue concentration in insecticides/fungicides (68%) and domestic market (70%)
  • Near-term margin pressure from raw material costs and R&D investment
  • Strategic shift toward bio-based pesticides in response to European market trends
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$769.9M
Gross profit$213.8M
Operating income$75.1M
Net income$66.6M
R&D
SG&A
D&A
SBC
Operating cash flow$100.5M
CapEx-$71.7M
Free cash flow$5.8M
Total assets$1.59B
Total liabilities$588.2M
Total equity$1.00B
Cash & equivalents
Long-term debt$170.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.00B
Net cash-$170.6M
Current ratio1.9
Debt/Equity0.2
ROA4.2%
ROE6.7%
Cash conversion1.5%
CapEx/Revenue-9.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric001231Activity
Op margin9.8%0.4% medp25 -8.0% · p75 16.0%above median
Net margin8.7%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin27.8%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-9.3%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity17.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 09:55 UTC#f581048e
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 11:42 UTCJob: 81dd773c